Products
Latanoprostenebunod was approved in the United States in 2017 in the form of eye drops (Vyzulta).
Structure and properties
Latanoprostenebunod is a prodrug that is metabolized in the eye to latanoprost acid and butanediol mononitrate. Butanediol mononitrate is further biotransformed to 1,4-butanediol and nitric oxide (NO). Latanoprost acid is also formed from latanoprost, which is also a prodrug.
Effects
Latanoprostenebunod lowers intraocular pressure. Latanoprost acid increases uveoscleral outflow of aqueous humor. It is an agonist at the prostaglandin F receptor (FP receptor). Nitric oxide (NO) increases aqueous humor outflow via the trabecular meshwork and Schlemm’s canal.
Indications
To lower intraocular pressure in open-angle glaucoma and ocular hypertension.
Dosage
According to the SmPC. The drops are placed in the conjunctival sac of the affected eyes once daily in the evening.
Contraindications
Latanoprostenbunod is contraindicated in case of hypersensitivity. For complete precautions, see the drug label.
Adverse Effects
The most common potential adverse effects include conjunctival hyperemia, ocular irritation, and local pain.
